Biotech Groups Sue Over Medicare Drug Pricing Model
Three industry groups allege federal health regulators exceeded their legal authority with a mandatory international-benchmark drug pricing program.
Updated on Nov. 7, 2026 in Healthcare
Live Poll
Should the federal government use international drug prices to lower Medicare costs?
The Biotechnology Innovation Organization, Biocom, and California Life Sciences filed a lawsuit on Friday against the Trump administration's Medicare drug pricing pilot. The suit alleges the Centers for Medicare & Medicaid Services exceeded its statutory authority in finalizing the rule.
Why it matters
The program ties Medicare prices for drugs administered in doctors' offices to lower prices in peer nations, a change that could reshape how the country pays for these medicines. The legal challenge raises questions about how far federal regulators can go in setting drug payment policy without new legislation.
Three biotechnology organizations, the Biotechnology Innovation Organization, Biocom, and California Life Sciences, filed the challenge against a program finalized on September 30. The lawsuit does not yet have a court ruling, and the program's effect on specific drug prices has not been quantified in the available information.
The players
Biotechnology Innovation Organization
The Biotechnology Innovation Organization is a major trade association representing biotechnology companies and research institutions across the United States and abroad.
Centers for Medicare & Medicaid Services
The Centers for Medicare & Medicaid Services is the federal agency that administers Medicare and Medicaid and oversees the programs that set payment rules for prescription drugs.
The details
The Centers for Medicare & Medicaid Services finalized the Global Benchmark for Efficient Drug Pricing model, a mandatory program that tests alternative methods for calculating rebates on Medicare Part B medicines. The model aligns Medicare drug prices with lower prices in peer nations and targets drugs administered in doctors' offices.
Timeline
September 30: CMS finalized the Global Benchmark for Efficient Drug Pricing model.
November 6: Three biotech industry groups filed the lawsuit challenging the model.
Health Landscape
The Global Benchmark model extends Medicare Part B payment policy by introducing mandatory international price benchmarks for drugs given in doctors' offices. The lawsuit tests whether the Centers for Medicare & Medicaid Services has the statutory authority to impose such a mechanism through rulemaking alone.
If the model takes effect, the rebate calculations could change how Medicare pays for drugs given in doctors' offices, which may affect the costs patients and providers see. Because the program is mandatory and the legal challenge is pending, its practical impact remains uncertain.
The takeaway
Pricing rules for Medicare drugs are being tested in court, and the outcome could influence how other federal health programs set payments. Readers tracking drug costs should watch whether the court ruling clarifies the agency's authority.
Further reading
Explore more in Healthcare for context on how federal drug pricing policy is shaping the industry.
Live Poll
Should the federal government use international drug prices to lower Medicare costs?
